Novavax announces H5N1 vax results; South Korea destroys smallpox vax doses;

Vaccine Research

Novavax released results from its Phase I/IIa H5N1 vaccine study, which showed no severe adverse events and protection against multiple clades of the virus. Novavax release

ImmunoCellular Therapeutics' Phase II brain cancer vaccine testing is underway, with trial enrollment scheduled by the second quarter of 2012, and results expected by the end of that year. The trial already has 36 patients enrolled of an estimated 150 to 160 total patients. Report

Dr. Samir Khleif has been named the new director of Georgia Health Sciences University Cancer Center in January. Khleif is the current chief of the National Cancer Institute's Cancer Vaccine Section. Item

Vaccine Market

Approximately 1 million doses of smallpox vaccine in South Korean stockpiles will be destroyed after the government found they were unfit for use due to high toxicity. Also, 4.59 million other doses have reached their expiration date. News

Selecta Biosciences is featured in this year's Fierce 15. Story

GlaxoSmithKline plans to use three companies for vaccine distribution in China, based on geographical regions. More

Inovio Pharmaceuticals has named Thomas Edgington and Philip Greenberg as new members of its scientific advisory board. Article

And Finally... Jeffrey Levi, executive director of the Trust for America's Health, analyzes the HPV vaccine conundrum for the Huffington Post. He proposes a new education campaign to help stimulate HPV vaccine uptake. Piece

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.